← Back to Patent Explorer
US4385066A Expired / Lapsed US ⏱️ 0.0 years remaining

Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions

Assignee: Beecham Group PLC
•
Filing: 1981-05-13
•
Granted: 1983-05-24
•
Expires: 2001-05-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds of formula (II): ##STR1## or a pharmaceutically acceptable salt, lower alkyl or aralkyl ester or amide thereof, wherein R 1 and R 2 , which may be the same or different, are each of a hydrogen atom or a methyl group, n is 1, 2 or 3, and Z is a C 1-6 alkyl or C 1-6 alkoxy group, or a halogen or hydrogen atom are useful in treating obesity and/or hyperglycaemia and/or inflammation in mammals.

Inventors

  • 👤 Anthony T. Ainsworth
  • 👤 David G. Smith

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 06:41
CPC Classifications
C; C07; C07C; C07C229/00; C07C229/38; A; A61; A61P; A61P29/00; A61P3/00; A61P3/08

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 60 words
A compound of formula (II): ##STR20## or a pharmaceutically acceptable salt, lower alkyl or aralkyl ester or amide thereof, in which R 1 and R 2 , which may be the same or different, are each hydrogen or methyl, n is 1, 2 or 3, and Z is a C 1-6 alkyl or C 1-6 alkoxy or halogen or hydrogen.
Claim 2
Dependent Claim 60 words
A compound of formula (II): ##STR20## or a pharmaceutically acceptable salt, lower alkyl or aralkyl ester or amide thereof, in which R 1 and R 2 , which may be the same or different, are each hydrogen or methyl, n is 1, 2 or 3, and Z is a C 1-6 alkyl or C 1-6 alkoxy or halogen or hydrogen.
Claim 3
Dependent Claim 45 words
A compound of formula (III): ##STR21## or a pharmaceutically acceptable salt, lower alkyl or aralkyl ester or amide thereof, wherein R 1 and R 2 , which may be the same or different, are each hydrogen or methyl and n is 1, 2 or 3.
Claim 4
Dependent Claim 45 words
A compound of formula (III): ##STR21## or a pharmaceutically acceptable salt, lower alkyl or aralkyl ester or amide thereof, wherein R 1 and R 2 , which may be the same or different, are each hydrogen or methyl and n is 1, 2 or 3.
Claim 5
Dependent Claim 17 words
A compound according to claim 1, in which R 1 is hydrogen and R 2 is methyl.
Claim 6
Dependent Claim 11 words
A compound according to claim 1, in which n is 1.
Claim 7
Dependent Claim 20 words
A compound according to claim 1, in which Z is methyl, ethyl, methoxy or ethoxy, or is chlorine or hydrogen.
Claim 8
Dependent Claim 18 words
A compound according to claim 1, in which the ester is the methyl, ethyl, propyl or benzyl ester.
Claim 9
Dependent Claim 9 words
The compound according to claim 1, which is N-(2-(4-carbomethoxyphenyl)-1-methylethyl)-2-hydroxy-2-(3-trifluoromethylphenyl)ethanamine.
Claim 10
Dependent Claim 36 words
A pharmaceutical composition for the treatment of obesity or hyperglycaemia, comprising an effective amount of a compound or a pharmaceutically acceptable salt, ester or amide thereof according to claim 1, together with a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim 11 words
A pharmaceutical composition according to claim 8, in unit dosage form.
Claim 12
Dependent Claim 23 words
A composition according to claim 9, in which each unit dose contains from 0.1 to 500 mg of said compound of formula (II).
Claim 13
Dependent Claim 37 words
A method of treating obesity in human or non-human animals, which comprises administering an effective, non-toxic amount of a compound or a pharmaceutically acceptable salt, ester or amide thereof according to claim 1 to the obese animals.
Claim 14
Dependent Claim 33 words
A method of treating hyperglycaemia, in humans, which comprises administering an effective, non-toxic amount of a compound or a pharmaceutically acceptable salt, ester or amide thereof according to claim 1 to hyperglycaemic humans.

References Cited (Backward Citations)

US3723524A Cited
US4086272A Cited
US3911008A Cited
US4140713A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-05-23 1986-11-22 1987-05-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-05-23 1990-11-22 1991-05-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-05-23 1994-11-22 1995-05-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag